The study of Gluquamin anti-aggregant properties for experimental renal failure

Abstract

Topicality. Chronic kidney disease (CKD) is one of the most common urinary system diseases, which leads not only to inevitable renal failure, but also to kidneys hemodynamics worsening and platelet activity increase. Therefore, when searching for a new agents for CKD treatment, it is advisable to study their anti-aggregant properties.Aim. Experimental study of Gluquamin drug effect on the platelet aggregation in con-ditions of renal failure development to justify its use in CKD therapy. Materials and Methods. Heiman’s active nephritis was used as a model of renal failure. The stimulated platelet aggregation was determined in rats using turbidimetric method with an aggregometer.Results and Discussion. Under the influence of Gluquamin on the 120th day of study there was a significant decrease of the ADP-induced platelet aggregation relatively to untreat-ed animals, which indicates a decrease of the blood level of activated platelet forms. Also in rats there was a decrease of the collagen-stimulated aggregation, which indicates a decrease of the sensitivity of platelets to the components of the vascular wall and basal membranes. At the same time according to Gluquamin influence degree was superior to the activity of compara-tive drugs quercetin and lespephril.Conclusions. Under the conditions of renal failure development on the background of glomerulonephritis in rats Gluquamin has a pronounced anti-aggregant effect, normalizes he-modynamics, rheological properties of blood and is a promising drug in CKD therapy.